Departments of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, and Lui Che Woo Institute of Innovative Medicine, The Chinese University of Hong Kong, Hong Kong, 999077, China.
Guangdong Provincial Key Laboratory of Virology, Institute of Medical Microbiology, Jinan University, Guangzhou, 510632, China.
Adv Sci (Weinh). 2022 Jan;9(3):e2103248. doi: 10.1002/advs.202103248. Epub 2021 Nov 23.
COVID-19 is infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and can cause severe multiple organ injury and death. Kidney is one of major target organs of COVID-19 and acute kidney injury (AKI) is common in critically ill COVID-19 patients. However, mechanisms through which COVID-19 causes AKI remain largely unknown and treatment remains unspecific and ineffective. Here, the authors report that normal kidney-specifically overexpressing SARS-CoV-2 N develops AKI, which worsens in mice under ischemic condition. Mechanistically, it is uncovered that SARS-CoV-2 N-induced AKI is Smad3-dependent as SARS-CoV-2 N protein can interact with Smad3 and enhance TGF-β/Smad3 signaling to cause tubular epithelial cell death and AKI via the G1 cell cycle arrest mechanism. This is further confirmed in Smad3 knockout mice and cells in which deletion of Smad3 protects against SARS-CoV-2 N protein-induced cell death and AKI in vivo and in vitro. Most significantly, it is also found that targeting Smad3 with a Smad3 pharmacological inhibitor is able to inhibit SARS-CoV-2 N-induced AKI. In conclusion, the authors identify that SARS-CoV-2 N protein is a key mediator for AKI and induces AKI via the Smad3-dependent G1 cell cycle arrest mechanism. Targeting Smad3 may represent as a novel therapy for COVID-19-asscoaited AKI.
新型冠状病毒肺炎由严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染引起,可导致严重的多器官损伤和死亡。肾脏是新型冠状病毒肺炎的主要靶器官之一,危重症新型冠状病毒肺炎患者常并发急性肾损伤(AKI)。然而,新型冠状病毒肺炎导致 AKI 的机制仍知之甚少,治疗方法仍然不明确且无效。本文作者报道,正常肾脏特异性过表达 SARS-CoV-2 N 可导致 AKI,在缺血条件下,小鼠的 AKI 加重。机制上,作者发现 SARS-CoV-2 N 诱导的 AKI 依赖于 Smad3,因为 SARS-CoV-2 N 蛋白可以与 Smad3 相互作用,并通过 G1 细胞周期阻滞机制增强 TGF-β/Smad3 信号传导,导致肾小管上皮细胞死亡和 AKI。这在 Smad3 基因敲除小鼠和 Smad3 缺失的细胞中得到进一步证实,缺失 Smad3 可防止 SARS-CoV-2 N 蛋白诱导的体内和体外细胞死亡和 AKI。最重要的是,作者还发现,用 Smad3 药理学抑制剂靶向 Smad3 能够抑制 SARS-CoV-2 N 诱导的 AKI。综上所述,作者确定 SARS-CoV-2 N 蛋白是 AKI 的关键介质,并通过 Smad3 依赖的 G1 细胞周期阻滞机制诱导 AKI。靶向 Smad3 可能为 COVID-19 相关性 AKI 提供一种新的治疗方法。